Search Site
Home >> Signaling Pathways >> Cell Cycle/Checkpoint >> Cyclin-Dependent Kinases

Cyclin-Dependent Kinases

Antibodies

  1. Cat.No. Product Name Information
  2. T1192 Phospho-CDK9 (Thr186) Antibody Polyclonal Phospho-CDK9 (Thr186) antibody, reacts with CDK9 phosphorylated at Thr186
  3. T1055 cdc2 Antibody Polyclonal cdc2 antibody, reacts with total cdc2 protein, cross reacts with CDK2 and CDK3
  4. T1056 CDK4 Antibody Monoclonal CDK4 antibody, reacts with total CDK4 protein
  5. T1191 Phospho-cdc2 (Tyr15) Antibody Polyclonal Phospho-cdc2 (Tyr15) antibody, reacts with cdc2, CDK2, and CDK5 phosphorylated at Tyr14

Biochemicals

  1. Cat.No. Product Name Information
  2. A8412 Dinaciclib (SCH727965) Top Seller CDK inhibitor
  3. A8326 AZD-5438 Top Seller Potent CDK1/2/9 inhibitor
  4. A8641 LEE011 orally available and highly specific CDK4/6 inhibitor
  5. A8882 THZ1 Top Seller CDK7 inhibitor
  6. B7716 Senexin A New Product
  7. B7464 TMCB New Product
  8. B7445 (R)-DRF053 dihydrochloride Dual CK1/cdk inhibitor
  9. B7128 Ryuvidine New Product
  10. B6956 NSC 625987 New Product
  11. B6935 Aminopurvalanol A New Product
  12. A8335 Palbociclib (PD0332991) Isethionate Top Seller Highly selective CDK4/6 inhibitor
  13. A8565 Purvalanol B Purvalanol B has been shown to be a cyclin-dependent kinase inhibitor.
  14. A8639 Deferasirox Deferasirox (marketed as Exjade) is a rationally-designed oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.
  15. A8640 Flavopiridol hydrochloride Flavopiridol hydrochloride is a pan-cdk inhibitor.
  16. B6892 NSC 693868 New Product
  17. B1233 CDK4 inhibitor CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.
  18. B5220 [Ala92]-p16 (84-103) New Product
  19. B8002 LY2857785 LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.
  20. B6720 Kenpaullone New Product
  21. B7063 Arcyriaflavin A New Product
  22. B7633 PF 4800567 hydrochloride New Product
  23. A8385 BMS265246 potent and selective CDK1/2 inhibitor
  24. A8501 PHA-848125 potent, ATP-competitive CDK inhibitor
  25. A3794 SB1317 novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3
  26. A3676 NVP-LCQ195 NVP-LCQ195
  27. A3575 LY2835219 free base LY2835219 free base
  28. A3417 Flavopiridol Flavopiridol
  29. A3336 CVT-313 CVT-313 is a cell-permeable purine analog that acts as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1).
  30. A3303 CGP60474 CGP60474 is a potent inhibitor of cyclin-dependent kinase (CDK).
  31. A3295 CDK9 inhibitor 2 CDK9 inhibitor 2
  32. A3294 CDK9 inhibitor CDK9 inhibitor is a novel, selective CDK9 inhibitor for the treatment of HIV infection.
  33. A3293 CDK inhibitor II CDK inhibitor II is a potent CDK inhibitor.
  34. A3266 BS-181 CDK inhibitor
  35. A3198 AT7519 trifluoroacetate AT7519 trifluoroacetate
  36. A3197 AT7519 Hydrochloride multi-CDK inhibitor
  37. A3806 SCH900776 S-isomer potent, selective and orally bioavailable inhibitor of checkpoint kinase Chk1
  38. A1980 SNS-032 (BMS-387032) Top Seller Potent and selective CDK inhibitor
  39. A1723 Roscovitine (Seliciclib,CYC202) potent CDK inhibitor
  40. A5459 PHA-793887 novel and potent CDK2, CDK5 and CDK7 inhibitor
  41. A5700 BS-181 HCl highly selective CDK7 inhibitor
  42. A5719 AT7519 multi-CDK inhibitor
  43. A1794 LY2835219 potent and selective CDK4/6 inhibitor
  44. A8316 PD 0332991 (Palbociclib) HCl Top Seller Highly selective CDK4/6 inhibitor
  45. A1986 Nu 6027 selective CDK1/2 inhibitor
  46. B4754 LDC000067 LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.
  47. B1083 LEE011 hydrochloride LEE011 Hcl is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
  48. A8642 R547 potent ATP-competitive CDK1/2/4 inhibitor
  49. B1084 LEE011 succinate LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
  50. B1085 LEE011 succinate hydrate LEE011 succinate hydrate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
  51. B1234 WHI-P180 hydrochloride WHI-P180 hydrochloride is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
  52. B3707 ML167 highly selective Clk4 inhibitor
  53. B3277 AMG 925 FLT3/CDK4 dual kinase inhibitor
  54. A8643 WHI-P180 WHI-P180 is a potent inhibitors [with IC50 = 4.0 microM for epidermal growth factor receptor (EGFR) kinase inhibition] of the EGFR tyrosine kinase as well as Janus Kinase 3.
  55. A4467 SU 9516 Potent, selective cdk2 inhibitor (IC50 values are 0.022, 0.04, 0.2, >10, >10, 18 and >100 μM for cdk2, cdk1, cdk4, PKC, p38, PDGFR and EGFR respectively). Inhibits pRb phosphorylation causing enhanced pRB/E2F complex formation and induces G1 and G2-M cell cycle arrest. Transcriptionally downregulates Mcl-1 and has antiproliferative, cytostatic and pro-apoptotic effects in vitro.
  56. B4736 THZ1 Hydrochloride THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].
  57. B4665 CDK7-IN-1